Get the Stockscreener App
16.66
0.79%
0.13
Pre-market:
16.60
-0.06
-0.36%
Lyell Immunopharma Inc stock is traded at $16.66, with a volume of 11,071.
It is up +0.79% in the last 24 hours and up +2.59% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$16.53
Open:
$16.33
24h Volume:
11,071
Relative Volume:
0.28
Market Cap:
$320.06M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-21.09
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-5.56%
1M Performance:
+2.59%
6M Performance:
+75.29%
1Y Performance:
-13.26%
1-Day Range:
$16.33
$16.88
1-Week Range:
$16.29
$17.69
52-Week Range:
$7.65
$30.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
16.66 | 317.56M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Volatility clustering patterns for Lyell Immunopharma Inc.2025 Bull vs Bear & Daily Entry Point Trade Alerts - newser.com
Will Lyell Immunopharma Inc. benefit from macro trendsWeekly Risk Report & Trade Opportunity Analysis Reports - newser.com
Tick level data insight on Lyell Immunopharma Inc. volatilityTrade Analysis Summary & Safe Capital Allocation Plans - newser.com
Is this a good reentry point in Lyell Immunopharma Inc.Recession Risk & Low Risk Entry Point Tips - newser.com
How to manage a losing position in Lyell Immunopharma Inc.July 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com
How to track smart money flows in Lyell Immunopharma Inc.July 2025 Update & Trade Opportunity Analysis - newser.com
Strategies to average down on Lyell Immunopharma Inc.Quarterly Profit Review & AI Powered Market Trend Analysis - newser.com
Real time social sentiment graph for Lyell Immunopharma Inc.Market Sentiment Report & Weekly Setup with High ROI Potential - newser.com
Technical signs of recovery in Lyell Immunopharma Inc.2025 Buyback Activity & Weekly Chart Analysis and Guides - newser.com
How institutional ownership impacts Lyell Immunopharma Inc. stock2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Published on: 2025-10-31 03:26:35 - newser.com
Is it too late to sell Lyell Immunopharma Inc.Portfolio Gains Report & Weekly Stock Performance Updates - newser.com
Is Lyell Immunopharma Inc. still worth holding after the dipWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Published on: 2025-10-30 06:17:45 - newser.com
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Thursday - MarketBeat
Published on: 2025-10-30 02:39:25 - newser.com
What hedge fund activity signals for Lyell Immunopharma Inc. stockWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Lyell Immunopharma Inc. stock overvalued by current metricsGap Down & Safe Entry Point Alerts - newser.com
Published on: 2025-10-28 05:46:43 - newser.com
Lyell Immunopharma Inc Stock Analysis and ForecastTrading Psychology Tips & Achieve Triple Digit Returns - earlytimes.in
Published on: 2025-10-27 19:50:03 - newser.com
Lyell Immunopharma’s LYL314 Study: A Promising Step in Lymphoma Treatment - TipRanks
Lyell Immunopharma’s New CAR T-Cell Therapy Trial: A Potential Game-Changer in Lymphoma Treatment? - TipRanks
Alphabet Inc. Decreases Holdings in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):